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Summary
This review provides an update on interdisciplinary treat-
ment for dizziness. Dizziness can have various causes
and the treatment offered should depend on the cause. Af-
ter reading this article, the clinician will have an overview
of current treatment recommendations. Recommenda-
tions are made for the most prevalent causes of dizziness
including acute and chronic vestibular syndromes,
vestibular neuritis, benign paroxysmal positional vertigo,
endolymphatic hydrops and Menière’s disease, vestibular
paroxysmia and vestibular migraine, cardiac causes, tran-
sient ischaemic attacks and strokes, episodic ataxia type
2, persistent postural-perceptual dizziness, bilateral
vestibulopathy, degenerative, autoimmune and neoplastic
diseases, upbeat- and downbeat nystagmus. Recommen-
dations include clinical approaches (repositioning ma-
noeuvres), medication (adding, removing or changing cur-
rent medication depending on aetiology), vestibular phys-
iotherapy, ergotherapy and rehabilitation, treatment of
chest pain or stroke units and operative interventions. If
symptoms are acute and severe, medication with antiverti-
go agents is recommended as a first step, for a maximum
period of 3 days. Following initial symptom control, treat-
ment is tailored depending on aetiology. To assist the clin-
ician in obtaining a useful overview, the level of evidence
and number needed to treat are reported whenever pos-
sible based on study characteristics. In addition, warnings
about possible arrhythmias due to medications are issued,
and precautions to enable these to be avoided are dis-
cussed.
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Introduction
This review summarises treatment approaches for different
types of vestibular syndromes with central and peripheral
aetiologies. It relates to prior reviews [1–3] and adds recent
developments in the field. It also complements the manu-
script on diagnostic procedures for dizziness in the emer-
gency department published in this journal [4]. Where no
studies exist, tentative recommendations based on clinical
expertise are made. This review aims at providing an
overview of currently available treatment strategies for
clinicians of different disciplines. Even though specialist
consultation might still be required, knowledge about cur-
rent treatment options facilitates interdisciplinary dialogue.
Acute vestibular syndrome
An acute vestibular syndrome consists of an acute onset of
dizziness associated with nystagmus, nausea, light-headed-
ness and balance problems and lasting longer than 24 hours
[5, 6]. In almost any acute vestibular syndrome, the follow-
ing symptomatic treatment can be prescribed for the first
3 days: an antihistamine such as dimenhydrinate orally 50
mg every 4–6 hours or as a suppository 150 mg once or
twice per 24 hours [1], an anticholinergic such as trans-
dermal scopolamine 1 mg every 72 hours [1], a benzodi-
azepine such as diazepam orally 5–10 mg every 4–6 hours,
or clonazepam orally 0.5 mg every 4–8 hours [1, 3]. Such
medications should, however, not be taken for more than
3 days, because they are believed to inhibit central com-
pensatory processes, and benzodiazepines have addictive
potential [1]. The evidence for recommending these three
medications for symptomatic treatment is rather weak. It is
based on expert opinion. On the other hand, experts have
observed thousands of patients in the German Dizziness
Center. For the future, it is necessary to perform prospec-
tive, comparative studies that permit the calculation of a
number needed to treat.
Before prescribing dimenhydrinate, an electrocardiogram
(ECG) should be recorded. A second ECG should be
recorded after initiating treatment with dimenhydrinate,
because it can cause a prolongation of the frequency cor-
rected QT interval. Consequently, there is the danger of the
Torsade-de-pointes arrhythmia, especially if the patient has
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a congenital or acquired long QTc interval, is also taking
other potentially QTc prolonging drugs in addition to di-
menhydrinate, or has other risk factors such as low serum
potassium levels. No absolute risk numbers can be pro-
vided, though, because patients with long QTc syndrome
are excluded from studies with QTc-prolonging agents. To
avoid putting patients at risk, we recommend an ECG. It is
particularly important to avoid combining QTc-prolonging
drugs. Instead, treatment alternatives should be considered.
It is noteworthy that benzodiazepines themselves can be
the cause of dizziness. Moreover, the combination of dif-
ferent benzodiazepines is discouraged. Antihistamines, an-
ticholinergics and benzodiazepines are also referred to as
antivertiginosa [1]. Prior to prescribing them, however, the
primary care physician can try to alleviate the symptoms
by other means. For example, if the patient suffers from
benign paroxysmal positional vertigo, a repositioning ma-
noeuvre is indicated. Examples of how to carry out this
manoeuvre are described in this review. If the primary care
physician cannot manage the symptoms, antivertigonosa
can be applied to treat acute episodes of dizziness [1]. Al-
though we are not aware of comparative trials that make
exact reference to the number of days for which they
should be administered, we suggest a prescription over a
maximum of 3 days in the recommended doses of dimen-
hydrinate, scopolamine and clonazepam [1, 3]. Although
the aim must be to refer the patient to the specialist as fast
as possible if treatment attempts by the emergency physi-
cian fail, not all patients get an immediate appointment. In
such a case, antivertigonosa are a good choice to control
the symptoms. Once the patient has seen the specialist, the
right diagnosis can be made and the treatment with antiver-
tigonosa can be stopped in favour of another treatment.
Acute unilateral vestibulopathy
An acute vestibular syndrome in which drug therapy might
be useful is acute unilateral vestibulopathy [1–3, 7–9]. A
detailed overview of the symptoms of acute vestibular syn-
drome is described in the accompanying article on diag-
nosis [4]. Dizziness is often linked to an oscillating visu-
al perception (oscillopsia), nausea, postural instability and
ataxia. The cause may be re-activation of herpes simplex
virus type 1 in the vestibular ganglia [1–3, 8, 9], although
there is no definite proof for this hypothesis [1–3].
To control acute symptoms, antivertiginosa [1–3, 8] can be
applied as described above. If the cochlea or the vestibu-
locochlear nerves are involved (also known as labyrinthi-
tis), this condition can be associated with hearing loss. In
this case, the patient should be referred to an ear, nose and
throat specialist. The vestibular nerve lies in a bony canal
and nerve ischaemia due to inflammation-related swelling
can be reduced by administration of methylprednisolone;
thereby vestibular function may recover [1–3, 10–13]. The
level of evidence in these studies ranges from 1 [12] to 3
[11, 13]. The number needed to treat ranges between two
and three in all three studies for corticosteroid treatment
versus no treatment. Note that one study [12] had no no-
treatment group, so the exact number needed to treat can
only be estimated from other studies on how many pa-
tients without treatment have spontaneous remission. It is
noteworthy that a 6-month follow-up showed no superior-
ity of corticosteroids over physical therapy [12], with even
a slight advantage for physical therapy over corticosteroid
treatment (level of evidence 1, number needed to treat 20).
Methylprednisolone should be administered in a daily oral
dose of 100 mg and this dose should be reduced by 20 mg
every fourth day [1–3]. Alternatively, prednisolone can be
administered. During treatment, patients’ blood sugar lev-
els should be monitored. The risk for gastric ulcers should
be considered. If the patient has a risk factor for gastric ul-
cers and if there is co-medication with non-steroidal anti-
inflammatory drugs or a high bleeding risk due to platelet
inhibitors or a therapeutic anticoagulation regimen in addi-
tion to cortisone, the administration of a proton pump in-
hibitor should be considered. We also recommend that pa-
tients at risk for osteoporosis receive a calcium and vitamin
D supplement, such as 1000 mg of calcium and 800 IU of
vitamin D daily.
There is evidence that physiotherapy, which can foster cen-
tral vestibular compensatory mechanisms [1–3], addition-
ally helps to control symptoms and is at least, if not more
effective, than corticosteroid treatment [12]. In particular,
there is evidence for significant symptom reduction fol-
lowing vestibular physiotherapy [8, 12, 14–21]. Vestibular
physiotherapy can help to train balance in uni- or bilateral
peripheral aetiologies or in visual vertigo [14–18]. There-
fore, physiotherapy should be initiated at first presenta-
tion. We consider physiotherapy to be at least as important
as pharmacotherapy. It is, however, necessary that the pa-
tient sees a physiotherapist who is specialised in vestibular
physiotherapy. Depending on the healthcare system, it may
be necessary to explicitly mention vestibular physiothera-
py on the prescription.
Stroke
Acute vestibular syndrome can also be caused by central
aetiologies, with cerebellar stroke being the most common
central cause [22].
Cerebellar stroke can mimic the signs of peripheral
vestibulopathy. Downbeat nystagmus is present in about
50% of cerebellar strokes [22, 23]. Consequently, a cere-
bellar infarction should always be considered as a differen-
tial diagnosis, even if peripheral vestibulopathic failure is
suspected [22]. As in brainstem strokes, gaze-evoked nys-
tagmus is a sensitive sign of a lesion within the cerebel-
lum [22, 24]. If recognised within the appropriate time-
frame and after exclusion of contraindications, thrombol-
ysis is indicated. Therefore, a neurologist should be in-
volved if stroke remains among differential diagnoses dur-
ing initial evaluation. If indicated, an intravenous or intra-
arterial thrombolytic agent should be administered within
the first 4.5 [1] to 6 hours [25]. Intravenous thrombolysis
consists of systemic administration of recombinant tissue
plasminogen activator to re-perfuse thrombotic occlusions.
Intra-arterial thrombolysis requires a catheter to be placed
near the thrombotic occlusion, with the aim of achieving
thrombolysis at the location of the blocked artery. Studies
and recommendations on thrombolysis, however, are sub-
ject to continuous re-evaluation. There are cases where pa-
tients benefit from thrombolysis even beyond 6 hours after
symptom onset. It is noteworthy that some patients often
have no symptoms other than dizziness, nystagmus and
imbalance [22]. For this reason, it is important to recog-
nise the symptoms and to correctly classify them as central
rather than peripheral causes. Even if no stroke is present,
audio and vestibular loss can reflect a significant steno-
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sis of the anterior inferior cerebellar artery [22, 26, 27]
and precede an imminent stroke [22, 26, 27]. Patients with
isolated hearing loss or dizziness may have a labyrinthine
stroke, as the inner ear receives its blood supply from the
vertebrobasilar system [22]. Labyrinthine stroke or steno-
sis of the internal auditory artery may not be recognised
with magnetic resonance imaging (MRI) [22]. Given that
approximately 20% of strokes are within the vertebrobasi-
lar circulation, isolated vertigo due to labyrinthine stroke
is not unusual. Whenever a significant stenosis is suspect-
ed, for example because of repeated transient ischaemic
attacks, an analysis of the blood vessels with either com-
puted tomography (CT) or MRI angiography is mandatory
[22, 28–30]. On one hand, it is important to recognise pre-
sent or imminent stroke to reduce the damage resulting
from ischaemia; on the other hand this treatment might it-
self result in harmful consequences [31–33]. If a transient
ischaemic attack or stroke is recognised, the start of treat-
ment was linked to an 80% risk reduction of additional dis-
ability due to a subsequent stroke [31]. This does not mean
that all patients need thrombolysis, but it means that the
transient ischaemic attack or stroke is recognised and treat-
ment is initiated, for example by beginning treatment with
platelet inhibitors, oral anticoagulants or a statin [32]. In
order to recognise significant stenoses, CT- or MR-angiog-
raphy is necessary and patients should be referred to cen-
tres where it is available. Harmful consequences and risks
of diagnostic tests and treatment, such as contrast-induced
nephropathy, need to be considered. Not all patients will be
candidates for systemic thrombolysis, for example patients
with isolated vertigo, which results in a zero value in the
National Institutes of Health Stroke Scale. The risk of sys-
temic thrombolysis includes potentially fatal intracranial
haemorrhages, which occur in 2% of patients within the
first couple of days after its application [33]. As an initial
guide as to whether the patient suffers from a stroke, sever-
al clinical tests have proved useful. They are described in
our accompanying manuscript on diagnosis and elsewhere
[4, 5, 22, 34–37].
Episodic vestibular syndromes
An episodic vestibular syndrome is defined as dizziness
lasting less than 24 hours. Consequently, it may consist of
a short episode or repeated short episodes. It can be asso-
ciated with nausea, balance problems, nystagmus or mo-
tion intolerance [38]. A prominent example of an episodic
vestibular syndrome is benign paroxysmal positional verti-
go, which will be described in the next section.
Benign paroxysmal positional vertigo and reposition-
ing manoeuvres
The most important therapeutic procedures to treat benign
paroxysmal positional vertigo, where otolithic debris is
moving inside a canal (canalolithiasis) [3, 39–43] or in-
side/near the cupula (cupulolithiasis) [39, 44–46], are repo-
sitioning manoeuvres. The majority of benign paroxysmal
positional vertigo is idiopathic. Known causal factors in-
clude ototoxic medication [47], prolonged bed rest [48],
cervical hyperextension [49], osteoporosis [50, 51], age
[52], and migraine [53]. There are prospects for treatments
and prophylaxis of some of these conditions, such as os-
teoporosis and migraine.
There are four types of benign paroxysmal positional ver-
tigo, depending on the involvement of a specific semicir-
cular canal. Diagnostic manoeuvres to identify the affected
canal are summarised in table 1, repositioning manoeu-
vres in figure 1. The most commonly involved semicir-
cular canals are the posterior ones [65] (90%). Note that
repositioning manoeuvres should be performed by trained
individuals, since an incorrectly applied manoeuvre might
induce an iatrogenic switch or conversion of the affected
canal, for example from a posterior benign paroxysmal po-
sitional vertigo to a horizontal benign paroxysmal posi-
tional vertigo [66–68]. Otolith repositioning should only
be performed after determination of the affected canal by
means of diagnostic positioning techniques. A detailed
overview of other individual manoeuvres can be found in
the literature [54]. In addition, figures 1A and 1B show the
correct head and body positions during repositioning ma-
noeuvres of the posterior semicircular canal.
Endolymphatic hydrops and Menière’s disease
Among the different episodic vestibular syndromes,
Menière’s disease has been extensively studied [1–3,
69–98]. It is characterised by recurrent attacks of dizziness,
hearing loss and the sensation of ear pressure, as well as
tinnitus, probably due to an endolymph hydrops (overpro-
duction or under-resorption of endolymph) [1–3, 86, 87].
As a result, there is recurrent leakage through the mem-
brane separating endolymph and perilymph spaces [1–3].
Hence, the therapeutic goal is to reduce the production or
to enhance the absorption of endolymph [1–3]. The de-
gree of individual suffering can sometimes appear alarm-
ing when the patient first presents to medical staff [92]. So
far, there are more than 6000 articles on Menière’s disease.
Articles cover a wide spectrum of therapeutic recommen-
dations [1–3, 69–91, 93–98]. The treatment of Menière’s
disease consists of several steps depending on the stage
and severity of disease [69]. The therapeutic goal is to
reduce the number of attacks in order to prevent future
vestibular deficits [69]. Conservative treatments include
salt restriction or the administration of diuretics [1–3,
Table 1: Benign paroxysmal positional vertigo, the affected semicircular canal, and the repositioning manoeuvre.
Affected semicircular canal Repositioning manoeuvre [3, 42–44, 46, 54, 55]
Posterior (Barany 1921 [56]) Epley [57]
Semont [58]
Horizontal geotropic (Mac Clure 1985 [59]) Barbecue, Gufoni for geotropic form [43, 60]
Horizontal apogeotropic (Baloh et al. 1995 [61]) Gufoni for ageotropic form [42]
Anterior (Bertholon et al. [62], Califano et al. 2014 [63]) Canalith repositioning technique (CRT) [64]
Note: A geotropic nystagmus beats towards the earth, ageotropic nystagmus beats in the opposite direction. Videos for illustration purposes are provided online at https://smw.ch/
en/article/doi/smw.2017.14566/.
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69–71, 89]. Whereas some authors recommend that ther-
apy can be initiated with salt restriction followed by di-
uretics [69], others doubt the benefits of this treatment ap-
proach and warn of potentially harmful consequences [70,
71] of salt restriction or diuretics. In our opinion, this ap-
proach is not recommended. Other conservative treatments
include the administration of an H1-agonist/H3-antagonist
(betahistine dihydrochloride) or its metabolites [69, 72–76,
88–91]. Betahistine dihydrochloride improves microcircu-
lation in the inner ear, resulting in better balance between
endolymph production and resorption [1, 2, 73–75, 88].
Although a recently published long-term, multicentre, dou-
ble blind, randomised, placebo-controlled study did not
find evidence for successful symptom control with be-
tahistine dihydrochloride [72], other results, including data
from a meta-analysis [76], suggest symptom control after
betahistine dihydrochloride administration [1–3, 76,
89–91]. Based on clinical experience with 112 patients
over a period of 12 months, it is recommended to admin-
ister 48 mg betahistine dihydrochloride orally three times
daily [1–3, 90]. In individual cases, this dose can be in-
creased up to 480 mg daily if no sufficient symptom alle-
viation is achieved after 3 months of treatment [1, 91].
As a second step, more invasive treatments, such as in-
tratympanic steroid injections, may be considered [1, 2,
77, 78, 93–96]. Such treatments, although invasive, still
have low complication rates and minimal side effects [1,
2]. Intratympanic instillations of 0.4–1 ml high-dose dex-
amethasone solution (12 mg/ml) [95] might also be effec-
tive, though not as effective as gentamycin instillation [1,
2, 96]. Double-blind, placebo-controlled trials demonstrat-
ed symptom reduction following intratympanic steroid in-
jection [78, 93]. In contrast to an aminoglycoside instilla-
Figure 1: Two examples of repositioning manoeuvres for benign
paroxysmal positional vertigo (BPPV) due to an affected posterior
semicircular canal.(A) The Epley manoeuvre. The patient sits on
the examination table, slightly off centre to the end of the table.
The head is turned 45° to the affected side. The patient is pushed
backwards in a lying position with the head hanging over the end
of the table in a brisk movement. This manoeuvre will cause dizzi-
ness and the patient should be warned beforehand. When the
dizziness stops the head is slowly turned to the other side facing
first the ceiling, then the other wall of the room and finally – also
turning the body in the direction of the head – the floor. Compli-
ance of and communication with the patient is essential to prevent
back injuries. The turning movement should be performed slowly,
taking into account the slowly moving stones and the high viscosity
in the semicircular canal. The patient will suffer from another
episode of dizziness when the head is turned away from the affect-
ed side. When the dizziness ceases the patient is pushed upright
into a sitting position. The last movement should be led by the doc-
tor because sitting on the side of the bed will again produce an
episode of dizziness.(B) The Semont manoeuvre. The patient is
seated opposite the doctor. The head is turned 45° away from the
affected side. The upper body of the patient is pulled sideways
leaving the head in the turned position. The patient is put in a half-
lying position looking upward to the ceiling. The patient should be
warned beforehand that this positioning can cause dizziness. The
patient is held in this position for more than 1 minute until the dizzi-
ness stops, then pulled in the opposite direction with a brisk move-
ment, to the other side of the bed, lying on the shoulder of the un-
affected side with the head facing the floor. The patient is held in
this position for the same time that as in the first position. Finally,
the patient is put again in the seated, primary position. The Se-
mont manoeuvre is a good alternative to the Epley manoeuvre for
patients with back problems. Nevertheless, the back and the neck
of the patient should be protected at all times. The manoeuvre can
tion (see third step below), however, it is not associated
with hearing loss [1, 2, 77, 78, 93–96].
As a third step, more invasive options are reserved for pa-
tients with intractable Menière's disease. Chemoablative
agents, such as gentamicin, proved successful in reducing
the attacks of Menière's disease [1–3, 79, 81, 82, 87, 98].
Its obvious downside is possible hearing loss [97], which
is the reason why it is recommended in patients with pre-
existing hearing loss. New protocols with low-dose frac-
tioned transtympanic application of gentamicin (diluted
gentamicin, 26.7 mg/ml, pH 6.4, weekly for 4 weeks) aim
to reduce the risk of hearing loss [83, 87, 98]. Gentamicin
damages the hair cells responsible for vestibular informa-
tion in the inner ear [80]. Hence, its prophylactic admin-
istration is associated with a decrease of attacks. It can al-
so cause hearing loss owing to the proximity of other hair
cells responsible for hearing. Surgical approaches are also
discussed in the literature [86]. Patients with hearing loss
might benefit from labyrinthectomy, whereas patients with
preserved hearing are candidates for selective vestibular
neurectomy with hearing preservation [99]. Other surgical
procedures such as endolymphatic sac surgery are not rec-
ommended owing to lack of evidence of beneficial effects
[86].
be repeated several times.
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In summary, the more invasive methods such as gentam-
icin treatment or neurectomy are more effective, but are
also associated with risks and adverse effects. We recom-
mend starting with the least invasive methods mentioned
in step 1 and slowly progressing to more invasive options
if the severity of symptoms cannot be controlled otherwise.
In any case, it is necessary to inform the patient about the
risks and to make sure that invasive procedures are carried
out by clinicians with the relevant experience. If the pa-
tient cannot be examined by a specialist immediately, clini-
cians without expertise regarding Menière’s disease should
consider administering antivertiginosa or betahistine dihy-
drochloride. Subsequently, the clinicians should make sure
that the patient is seen by a specialist.
Superior canal dehiscence syndrome
Superior canal dehiscence syndrome is an episodic
vestibular syndrome [100–104]. It consists of dizziness
combined with auditory symptoms such autophony, hyper-
acusis and tinnitus induced by sound or pressure. The rea-
son for this pressure transmission is a bony dehiscence of
the superior semicircular canal, first described by Minor in
1998 [101]. Surgical repair such as capping, re-surfacing
or plugging of the superior semicircular canal is recom-
mended [102–104].
Vestibular paroxysmia
Drug therapy may alleviate symptoms of vestibular parox-
ysmia [1, 2], which is recurrent attacks of spinning vertigo
persisting up to 1 minute [1, 2]. Vestibular paroxysmia may
rarely be accompanied by either tinnitus or decreased hear-
ing [1]. It often leads to unsteadiness of stance or gait and
can be provoked by a change in head position or by hy-
perventilation [1, 105, 106]. Its origin is probably a com-
pression of the eighth cranial nerve by blood vessels near
the brainstem [1, 2, 105–108]. Recommended medications
are oral carbamazepine 200–600 mg per day [1, 2, 106],
in some cases up to 800 mg per day [1], or oxcarbazepine
in slightly higher doses. The efficacy of oxcarbazepine to
relieve symptoms was demonstrated in a group of patients
who received a mean dose of 870 mg of per day [106]. For
both carbamazepine and oxcarbazepine, we recommend
starting with a low dose and progressing slowly to high-
er doses. The weakness of these recommendations is that
prospective, randomised, comparative trials do not exist.
Therefore, a number needed to treat cannot be computed.
The following recommendations in this section rely on ex-
pert opinion (level of evidence 5). Consequently, prospec-
tive studies with comparative treatment arms are strongly
encouraged.
If carbamazepine is not tolerated, there are alternatives,
such as phenytoin, gabapentin or valproate, although these
are not based on evidence [1, 2]. Patients therefore need to
be informed of the off-label administration. We would al-
so recommend looking for potential side-effects and con-
traindications, such as high-level atrioventricular block,
bradycardia, electrolyte imbalances, etc. In our opinion,
treatment should start with low doses: for example, in
adults 100 mg phenytoin orally once daily, which can be
subsequently increased up to three times per day (over the
next four to six days, increasing the dose every two to three
days). With gabapentin, the starting dose could be 300 mg
once on day one, to be increased to twice daily on day two
and three times daily on day three. Only if it shows par-
tial yet insufficient symptom relief would we recommend
a further increase. Because this is off-label use and empir-
ical evidence is lacking, we would not recommend a daily
dose higher than 1800 mg. Valproate dosing, on the other
hand, is more dependent on body weight. We would start
with 10 mg per kilogram body weight, and increase the
dose every three days to a maximum daily dose of 20 mg
per kilogram body weight. Antiepileptic medications can
themselves elicit dizziness [109, 110], so they should be
administered cautiously. We would also recommend that
they are prescribed only by a specialist who is able to dif-
ferentiate possible side effects from the sensation of dizzi-
ness per se and who carries out the necessary laborato-
ry checks. In particular, valproate can be associated with
blood count changes such as leucopenia and thrombopenia
or elevated liver enzymes.
Vestibular migraine
Another episodic vestibular syndrome of central origin is
vestibular migraine. It is characterised by attacks of either
dizziness alone or with stance and gait ataxia, headache,
nausea, vomiting and visual sensations [1–3]. These
episodes might last minutes to hours and can be first treat-
ed symptomatically with the previously mentioned antiver-
tigonosa [1]. For the future, prospective, placebo-con-
trolled clinical studies analysing vestibular migraine are
needed. The principles of migraine treatment can be ap-
plied to prevent attacks of vestibular migraine. We rec-
ommend prophylactic oral administration of topiramate
25–100 mg daily or valproate 300–900 mg daily [1, 111] or
the sustained release form of metoprolol 50–200 mg daily
[1, 112, 113]. There was no clear evidence for the benefits
of zolmitriptan in vestibular migraine [113, 114], whereas
slightly better effects were found for the prophylactic oral
administration of propranolol 40–240 mg daily [113, 115],
amitriptyline 50–100 mg daily [113, 116], flunarizine 5–10
mg daily [112, 113], and acetazolamide 250–750 mg dai-
ly [113, 117]. If the patient takes several medications, it is
necessary to check for drug-drug interactions and to con-
sider the QTc prolonging effect (see Introduction).
Cardiac causes and transient ischaemic attacks
Cardiac problems cause orthostatic dizziness, which can
be treated with compression stockings, but the majority of
cardiac causes identified in a systematic review were actu-
ally true vertigo [118]. Hence, whenever patients report the
sensation of dizziness, it is important to remember that this
could have a cardiovascular, valvular or arrhythmic origin.
In some cases, patients may benefit from revascularisa-
tion, valve repair/replacement or antiarrhythmic treatment.
If atrial fibrillation has persisted for more than 48 hours,
cardioversion into sinus rhythm should be attempted only
after exclusion of an atrial thrombus by transoesophageal
echocardiography.
As mentioned previously, stroke is also a potential cause of
dizziness. The same holds true for transient ischaemic at-
tacks, where patients may have isolated dizziness or other
stroke symptoms for less than 24 hours and without acute
ischaemic lesions on MRI. In addition, intermittent isolat-
ed vertigo may also be caused by vertebrobasilar insuffi-
ciency preceding a stroke [22, 26]. Patients who suffer a
transient ischaemic attack should undergo neurovascular
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ultrasonography to look for plaques or stenoses, echocar-
diography, and a long-term ECG to look for atrial fibril-
lation (if atrial fibrillation was not already present in the
ECG upon admission) [119]. Treatment of transient is-
chaemic attacks is a statin and aspirin [119]. The most
recent stroke prevention guidelines should be consulted
[119] and vascular risk factors should be sought. If the pa-
tient is on a factor Xa inhibitor for atrial fibrillation and
suffers from a transient ischaemic attack, anti-factor Xa
activity should be determined as a therapy check. If the
medication has insufficient effect, anticoagulant treatment
should be changed. If the transient ischaemic attack occurs
under previously established statin treatment, switching to
another statin should be considered, because, apart from
lipid levels, the plaque-stabilising effects of statins might
differ. Thromboendarterectomy or stenting should be con-
sidered in the case of symptomatic stenoses such as sub-
clavian artery stenosis or the rare cases of symptomatic
carotid stenosis associated with dizziness [119].
Episodic ataxia type 2
There are a number of inherited syndromes with recurrent
attacks of dizziness and ataxia [1–3, 120, 121]. Among
these inherited syndromes, episodic ataxia type 2 is the
most frequent [1]. Symptoms are dizziness and ataxia of
several hours duration, which are often elicited by physical
activity, alcohol consumption or stress [1–3]. Over 90%
of the patients have oculomotor disorders such as down-
beat nystagmus [1]. Successful treatment approaches in-
clude the administration of an aminopyridine [122–124].
Current recommendations include the off-label oral admin-
istration of 5 mg 4-aminopyridine three times daily [1, 2,
122] or the off-label oral administration of 10 mg of the
sustained release form dalfampridine once or twice daily
[1, 2, 123, 124].
Persisting vestibular syndromes
A chronic vestibular syndrome is a combination of symp-
toms with persistent dizziness lasting months to years and
other symptoms such as oscillopsia, nystagmus and gait
disturbance. They include persistent postural-perceptual
dizziness, bilateral vestibulopathic failure, degenerative,
autoimmune or neoplastic diseases, vestibular syndromes
with downbeat or upbeat nystagmus, and dizziness due to
isolated causes. Examples of the different chronic vestibu-
lar syndromes will be provided in the following sections.
Persistent postural-perceptual dizziness
Persistent postural-perceptual dizziness is an umbrella
term for known psychosomatic disorders such as sec-
ondary somatoform dizziness or phobic positional vertigo.
Phobic positional vertigo can be treated with vestibular
physiotherapy and cognitive behavioural therapy, possibly
combined with antidepressants such as selective serotonin
reuptake inhibitors [1, 3], for example citalopram 10–20
mg per day [1]. If selective serotonin reuptake inhibitors
are not sufficient, it is also possible to try serotonin norep-
inephrine reuptake inhibitors [125, 126]. It is necessary to
record an ECG prior to the initiation of and during treat-
ment with the antidepressant. In addition, it is necessary to
check the serum electrolytes, as many antidepressants can
be associated with low sodium levels.
Bilateral vestibulopathy
Bilateral vestibulopathy is characterised by postural im-
balance, gait impairment and, in some patients, oscillopsia
[127]. Its major cause is the administration of aminogly-
cosides such as gentamicin or streptomycin [127, 128].
Aminoglycosides are often used to treat severe infections
such as endocarditis. Other causes of bilateral vestibulopa-
thy are chemotherapy with cisplatin [127, 129] and au-
toimmune inner ear disease, which usually affects both
vestibular function and hearing [127] and may also have
ocular manifestations when parts of the peripheral or cen-
tral nervous system involving the eye are affected. Exam-
ples are autoimmune or infectious inflammatory processes,
neoplasms, traumas or malformations. Typical ocular ef-
fects happen during a probably autoimmune inflammation
of the cornea as in Cogan’s syndrome [127, 130]. Other
pathological mechanisms include bacterial or viral menin-
gitis [127], bilateral vestibular neuritis [127, 131, 132], bi-
lateral vestibular Schwannomas [127], bilateral Menière
disease [127, 133], neurosyphilis/neurolues [127, 134,
135], neurosarcoidosis [127, 136], congenital malforma-
tions [127] or head trauma [127, 137, 138]. It can be recog-
nised in the emergency department, at the bedside or in the
outpatient setting by comparing visual acuity during head
rotation with visual acuity when the head is still [127, 139,
140].
The underlying causes of bilateral vestibular loss need to
be eliminated or symptomatically treated, for example by
stopping aminoglycosides whenever possible. In general,
patients should be informed about possible side-effects pri-
or to starting treatment with aminoglycosides, so that they
can directly report to the clinician if these symptoms start.
If the full picture of vestibulopathy has developed, it most-
ly persists, because destroyed hair cells in the inner ear
do not regenerate [127] and only the future will show
whether molecular gene transfer approaches that work in
the mouse model will provide symptom relief in humans
[141]. Hence, the best approach is to stop the medication
when signs of vestibulopathy first develop, as some hair
cells may still be saved this way. In persisting bilateral
vestibular loss, the main approach to date is vestibular re-
habilitation by means of physiotherapy [16–18, 127, 142].
We recommend that physiotherapy is provided by an ex-
pert specialised in vestibular loss.
Degenerative, autoimmune and neoplastic diseases
It is necessary to apply anti-inflammatory treatment for
inflammatory lesions and autoimmune diseases [1], with
high-dose glucocorticoid treatment or other immunosup-
pressive or immune-modulating drugs [1].
Neurologists should be consulted if there is evidence for
an inflammatory lesion. Similarly, these lesions may be
caused by tumours or be the result of post-ischaemic
events. It is necessary to keep in mind that the symptoms
can be the same irrespective of the original cause, with the
location of the lesion determining what symptoms the pa-
tient may experience [1, 3].
Vestibular syndromes with downbeat or upbeat nys-
tagmus
Dizziness can be associated with vertical forms of nystag-
mus (downbeat or upbeat nystagmus) [1–3]. Both down-
beat and upbeat nystagmus usually coincide with sway
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vertigo and gait ataxia [1]. They have central aetiologies,
such as Arnold-Chiari malformation, cerebellar atrophy
and ischaemic or inflammatory lesions in the brainstem or
cerebellum, or are idiopathic [1, 143, 144]. Current rec-
ommendations include the off-label oral administration of
4-aminopyridine 5–10 mg two to three times daily in both
downbeat nystagmus [1–3, 145–147] and upbeat nystag-
mus [1–3, 148], the oral administration of 3,4-diaminopy-
ridine 10–20 mg two to three times daily [1–3, 149], or
the oral administration of clonazepam 0.5 mg three times
daily [1, 150–152]. Due to its addictive potential and the
impairment of central compensation mechanisms [1], we
do not recommend the administration of clonazepam for
more than 3 days. If the symptoms are minor, drug treat-
ment can even be omitted. Downbeat nystagmus will usu-
ally improve throughout the day [153], especially when the
head remains in an upright position [143]. According to re-
cent evidence from an observational study, it may be fur-
ther improved by resting in darkness with the head in an
upright position [154].
There are additional forms of nystagmus that go along
with dizziness, but these are less frequent than downbeat
or upbeat nystagmus. These less frequent forms of nystag-
mus, such as acquired pendular nystagmus or periodic al-
ternating nystagmus, are not be summarised here. Detailed
recent reviews and therapeutic recommendations can be
found elsewhere [1, 2, 152].
Dizziness due to isolated causes
Some cases of dizziness have a clearly defined origin.
These include peripheral neuropathy, for example due to
deficiency of vitamin B1, B6 or B12 or to diabetes. Rec-
ommended therapy is treatment of the vitamin deficiency
or better control of diabetes, in addition to physiotherapy
and ergotherapy (use of supportive equipment, adapted
shoes, etc.). Further isolated causes include ophthalmolog-
ical aetiologies, such as a decrease in visual acuity, de-
fects in visual fields or binocular vision, anisometropia,
multifocal acuity correction or metamorphopsia and par-
ticular forms of cataract [155]. In these cases, it is vital to
optimise ophthalmological treatment to reduce the sensa-
tion of dizziness. Dizziness following anaemia due to gas-
trointestinal blood loss requires identification of the cause
and specific treatment. Another cause of dizziness is cer-
vical vertigo [156], which could be due to degenerative
vertebral processes, trauma [157] or nerve compressions.
Treatment includes manual therapy, muscle relaxants or
anti-inflammatory medication [156], specific vestibular re-
habilitation [156, 157], and stress-reduction and anxiety-
reducing techniques [157]. More details on the specific
treatments are provided elsewhere [156, 157]. If there is a
significant nerve compression that cannot be treated con-
servatively, interventional approaches remain a therapeutic
option. Other isolated causes of dizziness include acute
infections (which require treatment according to the in-
fectious focus), and respiratory diseases associated with
hypercapnia. When the underlying aetiology is treated suc-
cessfully, the acute vestibular sensation may also disap-
pear. Such medical conditions could include either a single
cause, such as pulmonary embolism or myocardial infarc-
tion, an electrolyte imbalance, or an infection, or have mul-
tiple causes.
Conclusion
This review summarises current treatment recommenda-
tions for different forms of dizziness. Optimal treatment
strategies should be tailored to the individual patient and
underlying aetiology. They should involve multidiscipli-
nary approaches including neurology, ear-nose-throat, oph-
thalmology, general internal medicine, emergency medi-
cine and neurosurgery, physiotherapy and ergotherapy. In
many cases, it is possible to treat the symptoms of dizzi-
ness, but not to entirely reverse the cause, for example in
cerebellar stroke or bilateral vestibular loss. Many recom-
mendations are based on retrospective cohort studies (lev-
el of evidence 3), case series (level of evidence 4) and ex-
pert recommendations or case reports (level of evidence
5), which calls for future prospective studies with higher
levels of evidence. Given that dizziness is one of the most
frequent reasons why patients consult general practition-
ers and emergency departments, it is important to stimulate
future research. This would allow us to make recommen-
dations based on higher levels of evidence. It is partic-
ularly important to have comparative studies where dif-
ferent treatment approaches are compared with each other
and with placebo. The first steps in this direction have al-
ready taken place; for example, there is a multicentre, ran-
domised placebo-controlled trial underway on treatment of
vestibular paroxysmia (VESPA) [158]. Hopefully similar
trials will be made possible for the other causes of dizzi-
ness.
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